| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 24049 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab (Keytruda®) in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 04/12/2024 |
| Rapid review completed | 10/01/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/01/2025 |
